Clinical Trial Update: Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the effect of valsartan on lipid subfractions in adults with hypertension and metabolic syndrome; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Metabolic Syndrome

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis | Conditions: Hypertension, Metabolic Syndrome | Phase 3 | Status: COMPLETED